Mindray Medical announces completion of Wuhan Dragonbio acquisition

From MindrayJul 17 2015

Mindray Medical International Limited ("Mindray" or the "Company", NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today that it completed the acquisition of the remaining stake in Wuhan Dragonbio Surgical Implant Co., Ltd. (the "Dragonbio") for a total cash consideration of RMB 435 million (approximately US$ 70.2 million) pursuant to the terms of the definitive agreement entered into on July 7, 2015. The Company now holds 100% of Dragonbio. Dragonbio is a domestic medical orthopedic products provider that specializes in trauma, spine, joint and other surgical products.

Source:

Mindray Medical International Limited

Posted in: Business / Finance

Comments (0)

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

APA
Mindray. (2019, June 20). Mindray Medical announces completion of Wuhan Dragonbio acquisition. News-Medical. Retrieved on May 01, 2025 from https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx.
MLA
Mindray. "Mindray Medical announces completion of Wuhan Dragonbio acquisition". News-Medical. 01 May 2025. <https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx>.
Chicago
Mindray. "Mindray Medical announces completion of Wuhan Dragonbio acquisition". News-Medical. https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx. (accessed May 01, 2025).
Harvard
Mindray. 2019. Mindray Medical announces completion of Wuhan Dragonbio acquisition. News-Medical, viewed 01 May 2025, https://www.news-medical.net/news/20150717/Mindray-Medical-announces-completion-of-Wuhan-Dragonbio-acquisition.aspx.